Edgar Filing: AmpliPhi Biosciences Corp - Form 4

AmpliPhi B Form 4	iosciences Corp										
April 04, 20	17										
FORM	ЛЛ	STATES	SECU	RITIFS A	ND FX	CHANGE	COMMISSIO	NT	PPROVAL		
		STATES		ashington				N OMB Number:	3235-0287		
Check th if no lon subject t Section Form 4 d	ger STATEN 16.	/IENT OI	F CHAI	NGES IN SECUI	WNERSHIP OF	Expires: Estimated burden hou response	urs per				
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940											
(Print or Type	Responses)										
1. Name and A Martin Stev	2. Issuer Name and Ticker or Trading Symbol AmpliPhi Biosciences Corp [APHE				5. Relationship of Reporting Person(s) to IssuerB] (Check all applicable)						
(Last)	(First) (I	Middle)	3. Date of	of Earliest T	ransaction		(check an applicable)				
C/O AMPL CORPORA CENTRE I	(Month/Day/Year) 04/01/2017				Director 10% Owner X Officer (give title Other (specify below) Chief Financial Officer						
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			ıl	6. Individual or Joint/Group Filing(Check Applicable Line)				
SAN DIEG					_X_ Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(State)	(Zip)	Tal	ole I - Non-l	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8)	4. Securit nAcquired Disposed (Instr. 3, 4	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V	Amount	(D) Price					
Reminder: Rej	port on a separate line	e for each cl	ass of sec	urities bene	-	-	-				
					inforn requi	nation cont red to respo ays a curre	pond to the colle ained in this forn ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)		
	Tab					posed of, or convertible s	Beneficially Owner securities)	d			
1 7711 6 7			24 D			5 3 5 1					

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities

Edgar Filing: AmpliPhi Biosciences Corp - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8	5)	Securities Acquired (A Disposed of (Instr. 3, 4, 4) 5)	(A) or of (D)		(Instr. 3 and 4)		
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 0.43	04/01/2017		А		161,290		<u>(1)</u>	03/31/2021	Common Stock	161,290

Reporting Owners

Reporting Owner Name / Address	Relationships						
FB	Director	10% Owner	Officer	Other			
Martin Steven Robert C/O AMPLIPHI BIOSCIENCES CORPORATION 3579 VALLEY CENTRE DRIVE, SUITE 100 SAN DIEGO, CA 92130			Chief Financial Officer				
Signatures							
/s/ Steve R. 04/04/2017							

Martin <u>**</u>Signature of Reporting Person

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

Date

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The shares subject to the option are 100% vested and exercisable as of the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.